E-LIB Suche - Ergebnisse für: Perl, Alexander E.

1

Post-Transplant Frailty Phenotype Predicts Survival:

Hadjis, Ashley D. ; White, Griffin W. ; Gill, Saar I....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S407-S408 , 2024

Link: https://doi.org/10.1016/..

2

Preconditioning Frailty Phenotype Influences Survival and R..:

Sung, Anthony D. ; Koll, Thuy ; Gier, Shannon H....
Transplantation and Cellular Therapy. 30 (2024) 4 - p. 415.e1-415.e16 , 2024

Link: https://doi.org/10.1016/..

3

Clinical outcomes of hypomethylating agents plus Venetoclax..:

Abaza, Yasmin ; Winer, Eric S. ; Murthy, Guru Subramanian Guru...
American Journal of Hematology. 99 (2024) 4 - p. 606-614 , 2024

Link: https://doi.org/10.1002/..

4

Health-Related Quality of Life with Gilteritinib Versus Pla..:

Hamilton, Betty K. ; Levis, Mark J. ; Pandya, Bhavik J...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S44-S45 , 2024

Link: https://doi.org/10.1016/..

5

Hypomethylating agents are associated with high rates of he..:

Connor, Matthew P. ; Prathapa, Neeharika ; Frey, Noelle V....
Haematologica. , 2024

Link: https://doi.org/10.3324/..

6

POSTER: AML-132 QuANTUM-First Trial: FLT3–Internal Tandem D..:

Levis, Mark J. ; Erba, Harry P. ; Montesinos, Pau...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S166 , 2023

Link: https://doi.org/10.1016/..

7

Real‐world effectiveness of intensive chemotherapy with 7&3..:

Matthews, Andrew H. ; Perl, Alexander E. ; Luger, Selina M....
American Journal of Hematology. 98 (2023) 8 - p. 1254-1264 , 2023

Link: https://doi.org/10.1002/..

8

AML-132 QuANTUM-First Trial: FLT3–Internal Tandem Duplicati..:

Levis, Mark J. ; Erba, Harry P. ; Montesinos, Pau...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S272 , 2023

Link: https://doi.org/10.1016/..

9

Clofarabine and Busulfan Myeloablative Conditioning in Allo..:

Connor, Matthew P. ; Loren, Alison W. ; Hexner, Elizabeth O....
Transplantation and Cellular Therapy. 29 (2023) 2 - p. 113-118 , 2023

Link: https://doi.org/10.1016/..

10

P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RES..:

Levis, Mark J ; Erba, Harry P. ; Montesinos, Pau...
HemaSphere. 7 (2023) S3 - p. e446548f , 2023

Link: https://doi.org/10.1097/..

11

The FLT3N701K mutation causes clinical AML resistance to gi..:

Joshi, Sunil K. ; Pittsenbarger, Janét ; Kennedy, Vanessa E....
American Journal of Hematology. 98 (2023) 12 - p. , 2023

Link: https://doi.org/10.1002/..

12

S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATI..:

Schlenk, Richard ; Montesinos, Pau ; Romero-Aguilar, Antonio...
HemaSphere. 7 (2023) S3 - p. e61150fb , 2023

Link: https://doi.org/10.1097/..

13

CT-186 Impact of Allogeneic Hematopoietic Cell Transplantat..:

Schlenk, Richard F. ; Montesinos, Pau ; Romero-Aguilar, Antonio...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S521-S522 , 2023

Link: https://doi.org/10.1016/..

14

Oral Abstract: CT-186 Impact of Allogeneic Hematopoietic Ce..:

Schlenk, Richard F. ; Montesinos, Pau ; Romero-Aguilar, Antonio...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S148 , 2023

Link: https://doi.org/10.1016/..

15

Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory..:

Perl, Alexander E. ; Larson, Richard A. ; Podoltsev, Nikolai A....
Transplantation and Cellular Therapy. 29 (2023) 4 - p. 265.e1-265.e10 , 2023

Link: https://doi.org/10.1016/..